Company Overview
About Capstan Therapeutics
Capstan Therapeutics is a biopharmaceutical company founded in 2021 and headquartered in Philadelphia, Pennsylvania, with scientific co-founders including Drew Weissman (2023 Nobel Prize in Medicine laureate for mRNA technology) and Carl June (pioneer of CAR-T cell therapy). The company is developing a novel class of in vivo RNA-based medicines that use targeted lipid nanoparticles (LNPs) to deliver genetic instructions directly into specific immune cells inside the patient's body — enabling the creation of therapeutic immune cells (similar to CAR-T cells) without the costly and time-consuming ex vivo manufacturing process that currently requires extracting, engineering, and re-infusing a patient's cells outside the body.
Business Model & Competitive Advantage
Capstan raised a $165M Series A in 2022 led by a16z Bio and Newpath Partners, with participation from OrbiMed, 5AM Ventures, and other life sciences investors — one of the largest Series A rounds in biotechnology that year. The company's platform targets oncology (particularly blood cancers and solid tumors), fibrosis, and inflammation-related diseases. If successful, Capstan's approach could democratize cell therapy by eliminating the manufacturing bottleneck that limits current CAR-T therapies to a fraction of patients who could benefit, while dramatically reducing the cost and vein-to-vein time (currently weeks for ex vivo CAR-T).
Competitive Landscape 2025–2026
Capstan competes in the in vivo cell engineering space with companies including Umoja Biopharma, Orca Bio, and Cargo Therapeutics, as well as established CAR-T manufacturers (Novartis, Bristol Myers Squibb, Kite/Gilead) that are exploring in vivo approaches. The company's co-founder pedigree — combining the inventors of the mRNA technology underlying COVID vaccines with the pioneer of CAR-T — gives it exceptional scientific credibility in a field where platform differentiation is critical.
Key Differentiators
Emerging Innovator
Capstan Therapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Capstan Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Capstan Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Capstan Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Capstan Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →